<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641082</url>
  </required_header>
  <id_info>
    <org_study_id>CLV-401</org_study_id>
    <nct_id>NCT00641082</nct_id>
  </id_info>
  <brief_title>A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function</brief_title>
  <official_title>A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bukwang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      A double-blind randomized, parallel, multicenter with 48 weeks of treatment period. The
      purpose of this study is to compare the safety and antiviral activity of 48-week Clevudine
      and Adefovir dipivoxil in HBeAg(-) Chronic Hepatitis B with compensated liver function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with HBV DNA below 300copies/mL</measure>
    <time_frame>at week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of HBV DNA from the baseline</measure>
    <time_frame>at week 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HBV DNA below LOD of RT-PCR</measure>
    <time_frame>at week 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT normalization rate</measure>
    <time_frame>at week 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with viral breakthrough during 48-week treatment period</measure>
    <time_frame>at week 24, 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>HBeAg(-) Chronic Hepatitis B With Compensated Liver Function</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clevudine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adefovir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clevudine</intervention_name>
    <description>30mg for 48 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Levovir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir dipivoxil</intervention_name>
    <description>10mg for 48 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Hepsera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is between 18 and 60

          -  Patient is documented to be HBsAg positive for &gt; 6 months.

          -  Patient with compensated hepatic function.

          -  Nucleoside treatment-naÃ-ve subjects of either gender

          -  Patient is HBeAg negative. Patient is HBV DNA positive with DNA levels â‰¥ 1 x 10(5)
             copies/mL within 30 days of baseline.

          -  Patient has ALT levels which are in the range of 2 x ULN and &lt; 10 X ULN

          -  Patient who has not a history of ascites, variceal hemorrhage or hepatic
             encephalopathy.

        Exclusion Criteria

          -  Patient is currently receiving antiviral or corticosteroid therapy.

          -  Patients previously treated with lamivudine, adefovir, entecavir, telbivudine,
             clevudine, lobucavir, famciclovir or any other investigational nucleoside for HBV
             infection.

          -  Previous treatment with interferon must have ended at least 6 months prior to the
             screening visit.

          -  Treatment with nephrotoxic drugs, competitors of renal excretion, and/or hepatotoxic
             drugs within 2 months before study screening or during the study period

          -  Subjects who are currently participating in another investigational study or has been
             taking any investigational drug within the last 4 weeks prior to screening visit.

          -  Patient is coinfected with HCV, HDV or HIV.

          -  Patient with following clinical evidence

               -  Decompensated liver cirrhosis (Child class B,C: CPT score 7) or hepatocellular
                  carcinoma

               -  Significant gastrointestinal, renal, bronchopulmonary, neurological,
                  cardiovascular, oncologic or allergic disease

          -  Previous organ transplantation

          -  Patient has a clinically relevant history of abuse of alcohol or drugs.

          -  Patient is pregnant or breast-feeding.

          -  Patient is unwilling to use an &quot;effective&quot; method of contraception during the study
             and for up to 3 months after the use of study drug ceases.

          -  Patient has Î±-Fetoprotein more than 100ng/mL

          -  Patient has Hemoglobin &lt;11g/dL (Male), 10g/dL (Female) or WBC count &lt; 3,500/mm3
             (PMN&lt;1,500/mm3) or Platelet count &lt;50,000/mm3

          -  Patient has creatinine clearance less than 60mL/min as estimated by the following
             formula: (140-age in years) (body weight [kg])/(72) (serum creatinine [mg/dL]) [Note:
             multiply estimates by 0.85 for women]
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Bundang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2008</study_first_submitted>
  <study_first_submitted_qc>March 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2008</study_first_posted>
  <last_update_submitted>April 24, 2012</last_update_submitted>
  <last_update_submitted_qc>April 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2012</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Clevudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

